Deerfield Management Company, L.P. (Series C) Kiniksa Pharmaceuticals, Ltd. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$5.24 - $12.96 $6.68 Million - $16.5 Million	-1,274,086 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$8.15 - $15.88 $294,809 - $574,427	-36,173 Reduced 2.76%	1,274,086 $10.8 Million
Q1 2019 May 15, 2019	BUY	$15.93 - $26.59 $2.89 Million - $4.82 Million	181,437 Added 16.07%	1,310,259 $23.7 Million
Q4 2018 Feb 14, 2019	BUY	$16.25 - $28.09 $1.09 Million - $1.88 Million	66,866 Added 6.3%	1,128,822 $31.7 Million
Q3 2018 Nov 14, 2018	SELL	$13.23 - $30.93 $2.18 Million - $5.1 Million	-164,934 Reduced 13.44%	1,061,956 $27.1 Million
Q2 2018 Aug 14, 2018	BUY	$16.73 - $20.35 $20.5 Million - $25 Million	1,226,890 New	1,226,890 $21.3 Million

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$29.9 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

98.1K
Shares

$1.94 Million
0.08% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$779,453
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$592,200
0.51% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $680M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account